914637-80-2

Basic information

• Product Name: 4-OXOCYCLOHEXANECARBONYL CHLORIDE
• Synonyms: 4-OXOCYCLOHEXANECARBONYL CHLORIDE
• CAS NO: 914637-80-2
• Molecular Formula: C₇H₉ClO₂
• Molecular Weight: 160.6
• Product Categories: Carbonyl Chlorides;Carbonyl Chlorides;Ring Systems
• Mol File: 914637-80-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-OXOCYCLOHEXANECARBONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-OXOCYCLOHEXANECARBONYL CHLORIDE(914637-80-2)
• EPA Substance Registry System: 4-OXOCYCLOHEXANECARBONYL CHLORIDE(914637-80-2)

Safety Data

• Hazardous Substances Data: 914637-80-2(Hazardous Substances Data)

Upstream product

• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 6297-22-9 4-carbomethoxycyclohexanone 

Downstream Products

• 57452-32-1 2-(4-oxocyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino<2,1-a>isoquinolin-4-one 
• 945843-04-9 2-(trimethylsilyl)ethyl 4-oxocyclohexanecarboxylate 
• 945843-05-0 2-nitrobenzyl 4-oxocyclohexanecarboxylate 
• 134924-71-3 2-(4-trans-hydroxycyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino<2,1-a>isoquinolin-4-one 
• 134924-68-8 2-(4-cis-hydroxycyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino<2,1-a>isoquinolin-4-one 
• 897660-91-2 4-oxo-cyclohexanecarboxylic acid methyl-phenyl-amide 
• 1369537-36-9 4-[(4-fluorophenyl)amino]-N-methyl-N-(4-{[(3S)-3-methylpiperazin-1-yl]methyl}phenyl)cyclohexanecarboxamide 
• 1369537-37-0 tert-butyl (2S)-4-{4-[({4-[(4-fluorophenyl)amino]cyclohexyl}carbonyl)(methyl)amino]benzyl}-2-methylpiperazine-1-carboxylate 
• 1369414-28-7 tert-butyl (2S)-2-methyl-4-(4-{methyl[(4-oxocyclohexyl)carbonyl]amino}benzyl)piperazine-1-carboxylate 
• 945843-33-4 2-nitrobenzyl 15-oxo-7,11,18,21-tetraoxatrispiro[5.2.2.5.2.2]henicosane-3-carboxylate 
• 945843-26-5 2-nitrobenzyl 15-hydroxy-7,11,18,21-tetraoxatrispiro[5.2.2.5.2.2]henicosane-3-carboxylate 
• 945843-17-4 2-nitrobenzyl 15-[(4-methoxybenzyl)oxy]-7,11,18,21-tetraoxatrispiro[5.2.2.5.2.2]henicosane-3-carboxylate 
• 945843-16-3 2-(trimethylsilyl)ethyl 15-[(4-methoxybenzyl)oxy]-7,11,18,21-tetraoxatrispiro[5.2.2.5.2.2]henicosane-3-carboxylate 

Relevant articles and documents

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Visible-Light-Assisted Gold-Catalyzed Fluoroarylation of Allenoates

A strategically novel synthetic method for the fluoroarylation of allenic ester was developed that enables the expedient construction of a host of β-fluoroalkyl-containing cinnamate derivatives. The reaction proceeds through visible-light-promoted gold redox catalysis, occurs smoothly under very mild reaction conditions, accommodates a large variety of functional groups, and more importantly allows the incorporation of fluorine and aryl groups with excellent regio- and stereoselectivity. The concomitant activation mode for both the allene motif and the hydrogen fluoride is key for the success of the reaction.

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), (II-ii), (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

CYCLOHEXANE DERIVATIVE COMPOUND

To find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, the agent having excellent activity and high safety. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents an optionally substituted phenylene group; B represents an optionally substituted 4- to 10-membered heterocyclic group, an optionally substituted C6-C10 aryl group, or an optionally substituted C3-C10 cycloalkyl group; R1 represents a hydrogen atom or a C1-C3 alkyl group; R2 represents a hydrogen atom or a C1-C3 alkyl group; R3 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C3 alkoxy C1-C3 alkyl group, or a C1-C3 hydroxyalkyl group; R4 represents a hydrogen atom, a C1-C6 alkyl group, or a halogen atom; n represents an integer of 1 to 4; and X represents methylene, -O-, -NH-, -N(C1-C3 alkyl)-, -C(=O)-, -S-, -S(O)-, -S(O2)- or a single bond.

2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS

The invention relates to novel tetrahydro-1H-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.

PYRROLIDINE DERIVATIVES AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS

The invention relates to pyrrolidine derivatives of formula wherein R1,R2,R3,n, and o are defined in the specification and to pharmaceutically active acid-addition salts thereof. Compounds of formula I have a high affinity

Oligospiroketals as novel molecular rods

A modular approach for the synthesis of molecular rods based on oligospiroketals has been developed. The strategy relies on different terminal and intermediate segments, which are joined by ketal formation between ketones and diols. For this purpose it was necessary to develop a new ketalization method to circumvent some problems related with the established methods. The terminal segments are either derived from 4-piperidinone or from 4-oxocyclohexane carboxylic acid whereas the intermediate segments rest on pentaerythritol and cyclohexane-1,4-dione. A series of trispiro (14-18), hexaspiro (19) and nonaspiro (20) compounds have been prepared and characterized. From these we realized that it is imperative to use solubility enhancing groups if more than seven rings are joined.

2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS

The invention relates to novel tetrahydro-lH-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.